Cuba Begins Phase III of Domestic Latin American Vaccine
HAVANA, CUBA (AP) – –
Cuba will begin Phase III clinical trials of two of its own vaccine candidates against the new coronavirus next week, which could make it the first country in Latin America to obtain a fully tested and domestically manufactured immunization product.
Given the positive results of Phases I and II, the most advanced vaccine in development, Sovereign 02, is already being produced on an industrial scale.
Cuban scientists say they will have the capacity to manufacture 110 million doses throughout 2021, to which would be added another undetermined number from the Abdalá vaccine candidate.
The four Cuban candidates are, in addition to Soberna 02 and Abdalá, which are the most advanced, Mambisa and Soberana 01.
None of these products are produced from live virus.
The scientists indicated that the results of Phases I and II, which are basically aimed at determining that the product is safe, were published in two articles.
Now a third is expected to be released for their peers to review as established by the international community of specialists combatting COVID-19.
Phase III of the Sovereign and Abdalá will begin between March 3 and 8, which means people on the island will begin receiving the vaccines.
Cuba is experiencing a second wave of COVID-19 starting at the beginning of the year after commercial flights were reopened and isolation measures were de-escalated.
On Thursday authorities reported that since the start of the pandemic in March 2020, 47,566 people were infected and 312 have died.